SCHEMBL718578

SCHEMBL718578

COC(=O)c1ccc(NC(c2oc3ccc(F)cc3c2C)C2CCCCC2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
PDE7A Q13946 1/20 0.44
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
HCRTR1 O43613 1/20 0.36
PPARG P37231 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
DGAT1 O75907 1/20 0.36
RXFP1 Q9HBX9 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 3/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718462 0.91 NPC1 (0.48) NPC1RAB9AHCRTR1PPARGNCOR2
SCHEMBL14905708 0.87 NPC1 (0.48) NPC1RAB9AHCRTR1PPARGNCOR2
SCHEMBL716326 0.84 NPC1 (0.46) NPC1RAB9AGABRA5RXFP1KMT2A
SCHEMBL716695 0.84 GCGR (0.48) NPC1RAB9A
SCHEMBL10284478 0.84 RAB9A (0.42) NPC1RAB9APDE7AHCRTR1PPARG
SCHEMBL717961 0.83 NPC1 (0.42) NPC1RAB9APDE7ADGAT1MAPT
SCHEMBL719457 0.83 RAB9A (0.44) NPC1RAB9APDE7AKMT2AMEN1
SCHEMBL721439 0.82 NPC1 (0.51) NPC1RAB9APDE7AHCRTR1PPARG
SCHEMBL717908 0.82 RAB9A (0.39) NPC1RAB9APDE7AMAPTKDM4E
SCHEMBL14905653 0.81 NPC1 (0.49) NPC1RAB9APDE7AHCRTR1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885PDE7A 2449/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885PDE7A 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.